Company Encyclopedia
View More
name
CIRC
01763.HK
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test kits and analyzers. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services.
80.41 B
01763.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care SuppliesIndustry
Industry Ranking3/13
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.63%B
    • Profit Margin5.56%C
    • Gross Margin51.07%B
  • Growth ScoreB
    • Revenue YoY13.84%B
    • Net Profit YoY6.18%C
    • Total Assets YoY16.01%A
    • Net Assets YoY10.70%B
  • Cash ScoreB
    • Cash Flow Margin1797.09%B
    • OCF YoY13.84%B
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreC
    • Gearing Ratio49.14%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    China Isotope & Radiation Corporation and CNNC Capital Sign Strategic Cooperation Agreement

    China Isotope & Radiation Corporation (CIRC) and CNNC Capital Holdings Limited have signed a strategic cooperation agreement. The partnership aims to integrate the nuclear technology application industry chain, address technology bottlenecks, and cultivate new productive forces. They will collaborate through resource sharing, mergers and acquisitions, company establishment, equity investment, and securities business to support CIRC’s high-quality development with enhanced financial capital.

    Reuters·
    HK
    01763
    +1.92%
    Reuters·
    HK
    01763
    +1.92%

    China Isotope & Radiation Corporation Signs Contract to Supply Irradiation Equipment to Peru

    China Isotope & Radiation Corporation (CIRC) has signed a contract to supply gamma irradiation equipment to Peru for the Agricultural Gamma Irradiation Station Project. This project aims to improve sterilization, extend shelf life, and enhance the export quality of Peruvian agricultural products. This is CIRC's first export of such equipment to Latin America.

    Reuters·
    HK
    01763
    +1.92%
    Reuters·
    HK
    01763
    +1.92%

    China Isotope & Radiation Corporation Signs Cobalt-60 Supply Agreement with Brazil's CNEN

    China Isotope & Radiation Corporation (CIRC) has signed an agreement with Brazil's National Nuclear Energy Commission (CNEN) to supply cobalt-60 radioactive sources. This marks CIRC's first export of cobalt-60 to Latin America, enhancing Brazil's irradiation capacity for research and development. The agreement follows a Memorandum of Understanding signed in October 2025.

    Reuters·
    HK
    01763
    +1.92%
    Reuters·
    HK
    01763
    +1.92%

    Circle (Minutes): The Ecological Network is More Important than Commercialization

    The following are the Minutes of the $Citigroup(C.US)ircle (CRCL.US) FY25 Q3 earnings call. For a quick interpretation, you can simply review the Quick Interpretation of the financial report. 1. Financial Core Data Review: (1) Performance Overview: USDC circulation reached $73.7 billion, a year-on-year increase of 108%; on-chain transaction volume was $9.6 trillion, a year-on-year increase of 580%. (2) Profitability: Total revenue and reserve earnings were $740 million, a year-on-year increase of 66%; Adjusted EBITDA was $166 million, a year-on-year increase of 78%. The profit margin reached 57%...

    US
    CRCL
    +1.36%
    US
    DEFI
    -0.52%
    UK
    HSBA
    0.00%
    US
    CRCL
    +1.36%
    US
    DEFI
    -0.52%
    UK
    HSBA
    0.00%

    CIRC’s Breath Diagnostic Product Wins National-Level Champion Award

    China Isotope & Radiation Corporation (CIRC) announced that its subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has received the National-Level Manufacturing Enterprise recognition and the ‘Single-Item Champion in the Pharmaceutical Industry’ award for its Urea [13C/14C] Breath Test Kits. This achievement highlights CIRC's leadership in breath diagnostics and commitment to innovation. The current analyst rating for CIRC's stock (HK:1763) is a Buy, with a price target of HK$21.00, and the company has a market cap of HK$6.19B.

    Tip Ranks·
    HK
    01763
    +1.92%
    Tip Ranks·
    HK
    01763
    +1.92%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer